Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR1 | P16066 | 1/20 | 0.59 |
| ▸ | NPR3 | P17342 | 1/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.58 |
| ▸ | BAD | Q92934 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.55 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 2/20 | 0.50 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.49 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.49 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15186042 | 0.77 | BCL2L1 (0.61) | NPR1NPR3BCL2L1BADCACNA1B | |
| Carperitide SCHEMBL218549 | 0.77 | NPR1 (0.94) | NPR1NPR3BCL2L1BADRXFP4 | |
| SCHEMBL29376235 | 0.74 | NPR1 (0.88) | NPR1NPR3RXFP4RXFP3KCNMA1 | |
| Acetic Acid SCHEMBL29363649 | 0.74 | NPR1 (0.87) | NPR1NPR3CACNA1BKCNMA1KCNMB4 | |
| Ularitide SCHEMBL27908491 | 0.73 | NPR1 (0.79) | NPR1NPR3RXFP4RXFP3F11 | |
| SCHEMBL29711548 | 0.73 | NPR1 (0.86) | NPR1NPR3RXFP4RXFP3KCNMA1 | |
| Hydrochloric Acid SCHEMBL29495482 | 0.72 | NPR1 (0.85) | NPR1NPR3RXFP4RXFP3KCNMA1 | |
| SCHEMBL29352842 | 0.72 | BECN1 (0.63) | NPR1NPR3RXFP4RXFP3KCNMA1 | |
| Ziconotide SCHEMBL29369952 | 0.72 | CACNA1B (1.00) | NPR1NPR3CACNA1B | |
| Ziconotide SCHEMBL676878 | 0.72 | CACNA1B (1.00) | NPR1NPR3CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713019-A2 | CPG CONJUGATES AND METHODS OF USE | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-03-25 | — | — | EP | claimed |
| CN-118949049-B | Medicine assembly and preparation method and application thereof | 国家纳米科学中心 | 2025-02-21 | — | — | CN | claimed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | claimed |
| WO-2024238677-A2 | CPG CONJUGATES AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-11-21 | — | — | WO | claimed |
| CN-115353555-B | Quaternized chitosan oligosaccharide-mu-conotoxin conjugate as well as preparation method and application thereof | 山东大学 | 2024-04-30 | — | — | CN | claimed |
| CN-114573674-B | Alpha 9 alpha 10nAChR inhibitory active peptide and application thereof | 中国海洋大学 | 2023-11-14 | — | — | CN | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-116836255-A | Chemical synthesis preparation method of mu-conotoxin peptide | 广州森升生物科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116392602-A | Amphiphilic polypeptide carrier and application thereof | 国家纳米科学中心 | 2023-07-07 | — | — | CN | claimed |
| CN-114853864-B | nAChR receptor alpha 3 beta 2 subtype inhibition inactivation type blocking agent, and preparation method and application thereof | 海南大学 | 2023-06-20 | — | — | CN | claimed |
| CN-110981967-B | Dimer of alpha-conotoxin Mr1.1, synthetic method and application | 中国海洋大学 | 2022-10-14 | — | — | CN | claimed |
| US-20220257785-A1 | KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-08-18 | — | — | US | claimed |
| EP-4037709-A1 | KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114585382-A | Kink-immunostimulatory conjugates and related compositions and methods | 小利兰·斯坦福大学理事会 | 2022-06-03 | — | — | CN | claimed |
| EP-3972647-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-03-30 | — | — | EP | claimed |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4713019-A2 | CPG CONJUGATES AND METHODS OF USE | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3946411-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | The Trustees of Columbia University in the City of New York (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | NPR1 2626/4885NPR3 2865/4885BCL2L1 2528/4885 |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | SHMT2, NLN, TFAM | NPR1 3476/4885NPR3 3994/4885BCL2L1 273/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | NPR1 554/4885NPR3 1316/4885BCL2L1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.